Madrid

• A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr … Ended
  2023-508663-70-00 4 2024-06-18 Bronchiectasis
• A study on the immune response and safety of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccin … Ended
  2023-510196-59-00 5 2024-06-15 Respiratory Syncytial Virus Infections
• A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy. Ended
  2023-504892-25-00 5 2024-06-14 Narcolepsy
• Bioequivalence clinical trial of two formulations of linagliptin Ended
  2023-506562-31-00 2 2024-06-14 Healthy volunteers
• An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulation Ended
  2023-507630-25-00 3 2024-06-14 Infertility in women undergoing assisted reproductive technologies (AR
• EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer Ended
  2023-509336-25-00 9 2024-06-12 Metastatic castration-resistant prostate cancer
• A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined with Atezolizumab in Non-Hodgkin's … Ended
  2023-506820-10-00 9 2024-06-11 B-Cell Malignancies
• Bioequivalence clinical trial of two formulations of edoxaban. Ended
  2024-510795-20-00 2 2024-06-11 Healthy volunteers
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR Ended
  2023-507667-19-00 3 2024-06-06 Polymyalgia rheumatica (PMR)
• AMX0035 and Progressive Supranuclear Palsy Ended
  2023-505893-14-00 5 2024-06-04 Progressive Supranuclear Palsy
• A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Te … Ended
  2023-509077-23-00 5 2024-06-03 Ataxia Telangiectasia
• Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to … Ended
  2024-512311-41-00 2 2024-06-03 Parkinson´s disease
• Phase 2 study comparing SAR447537 to plasma-derived A1PI therapy for AATD emphysema Ended
  2023-508084-76-00 4 2024-05-31 Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
• A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months Ended
  2022-502022-41-00 3 2024-05-28 Acute lower respiratory infection
• Open-label, prospective study to assess the safety, tolerability, analgesic effect and feasibility of IN SUF/KET in pediatric patients with … Ended
  2023-504023-63-00 4 2024-05-24 Pain
• A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended
  2023-507324-23-00 4 2024-05-22 recurrent or persistent uterine serous carcinoma
• A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations Ended
  2022-502595-23-00 7 2024-05-21 Patients with locally advanced or metastatic non-small cell lung cance
• Temocilin vs meropenem for the treatment of infections due to Enterobacteriales Ended
  2023-508440-21-00 5 2024-05-21 Infections due to Enterobacteriaceae
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2023-506557-38-00 5 2024-05-16 Dermatitis atopic
• A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)- … Ended
  2023-506881-30-00 3 2024-05-15 Melanoma
• Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas Ended
  2024-510877-67-00 8 2024-05-14 Phase I:Adult patients with centrally confirmed diagnosis of advanced/
• A Phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of Azeliragon combined with conventional con … Ended
  2024-512954-96-00 9 2024-05-14 Glioblastoma
• A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended
  2023-507682-25-00 4 2024-05-13 Chronic heart failure with reduced ejection fraction

Showing 2,761–2,784 of 3,550 trials